There are currently 1140 clinical trials in Cincinnati, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of Cincinnati Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Recruiting
The Increlex® Global Registry is a descriptive, multicenter, observational, prospective, open-ended, non interventional, post-authorisation surveillance registry. The main purpose of this global registry is to collect, analyse and report safety data during and up to at least 5 years after the end of treatment in children and adolescents receiving Increlex® therapy for SPIGFD according to the locally approved product information.
Gender:
All
Ages:
Between 2 years and 18 years
Trial Updated:
05/30/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: IGF1 Deficiency
A Study of IMPT-514 in Active Refractory Systemic Lupus Erythematosus (SLE)
Recruiting
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-514, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with active, refractory lupus nephritis and systemic lupus erythematosus. IMPT-514 treatment consists of a single infusion of CAR-transduced autologous T cells administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide. Individual... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: University of Cincinnati (UC) - Department of Nephrology, Cincinnati, Ohio
Conditions: Systemic Lupus Erythematosus, Lupus Nephritis
Registry Study for Radiation Therapy Outcomes
Recruiting
The purpose of this research study is to collect and analyze information from patients being treated with various forms of radiation therapy.
Gender:
All
Ages:
All
Trial Updated:
05/30/2024
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Neoplasms
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
Recruiting
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus background pulmonary arterial hypertension (PAH) therapy) versus placebo (plus background PAH therapy) on time to clinical worsening (TTCW) in participants who are newly diagnosed with PAH and are at intermediate or high risk of disease progression.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital ( Site 1001), Cincinnati, Ohio +1 locations
Conditions: Pulmonary Arterial Hypertension
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Recruiting
The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR) per RECIST v1.1. This study will also assess other measures of antitumor activity; overall survival (OS); as well as the safety and tolerability of enfortumab vedotin for cohorts 1 to 8 and enfortumab vedotin + pembrolizumab in cohort 9.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Locally Advanced or Metastatic Malignant Solid Tumors
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Recruiting
The purpose of the phase 1 portion (dose escalation) of the study will be to establish an optimally safe and biologically active recommended phase 2 dose (RP2D) and/or to determine maximum tolerated dose (MTD) for gilteritinib in sequential combination with fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG). The purpose of the phase 2 portion (dose expansion) is to determine complete remission (CR) rates and composite complete remission (CRc) rates after two cycles of thera... Read More
Gender:
All
Ages:
Between 6 months and 21 years
Trial Updated:
05/29/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
Study in Parkinson Disease of Exercise
Recruiting
This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson disease. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax or 2)80-85% HRmax 4 times per week. The primary objective is to test whether the progression of the signs of Parkinson's disease is attenuated at 12 mon... Read More
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
05/29/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Parkinson Disease
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
Recruiting
The purpose of this study is to evaluate the benefits and risks of conversion of existing adolescent kidney allograft recipients aged 12 to less than 18 years of age to a belatacept-based immunosuppressive regimen as compared to continuation of a calcineurin inhibitor-based regimen and their adherence to immunosuppressive medications.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
05/29/2024
Locations: Local Institution - 0025, Cincinnati, Ohio
Conditions: Renal Allograft Recipients
Let's K-Talk - HPV Study for Ethnic Koreans
Recruiting
The goal of this clinical trial is to test the feasibility, acceptability, and preliminary efficacy of a storytelling video-based intervention using AI chatbot technology (K-Talk) to promote HPV vaccination behavior among Korean Americans aged 18 to 45. The main questions this study aims to answer are: Is the K-Talk intervention feasible for use among Korean Americans aged 18 to 45? Is the K-Talk intervention acceptable to the target population? What is the preliminary efficacy of the K-Talk i... Read More
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
05/29/2024
Locations: Minjin Kim, Cincinnati, Ohio
Conditions: Human Papillomavirus Viruses, Papillomavirus Vaccines
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Recruiting
TransCon TLR7/8 Agonist is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This Phase 1/2 study will evaluate TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab in dose escalation and dose expansion. Participants will receive intratumoral (IT) injection of TransCon TLR7/8 Agonist every cycle. The primary objectives are to evaluate safety and tolerability, and define the Maximum Tolerated Dose (MTD) and Recommended Pha... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/29/2024
Locations: Ascendis Pharma Investigational Site, Cincinnati, Ohio
Conditions: Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma HNSCC, HPV-associated Cancers, Neoadjuvant Melanoma, Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)
Study of ALTO-300 in MDD
Recruiting
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/29/2024
Locations: Site 202, Cincinnati, Ohio
Conditions: Major Depressive Disorder
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Recruiting
The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature B-cell non-Hodgkin lymphoma (B-NHL).
Gender:
All
Ages:
Between 6 months and 30 years
Trial Updated:
05/29/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Mature B-Cell Non-Hodgkin Lymphoma